Groundbreaking Dual-Action Therapy CG-0416 Revolutionizes Obesity Management at 2025 EASL Congress

At the 2025 EASL Congress: A New Era in Obesity and Liver Health



In an exciting announcement at the European Association for the Study of the Liver (EASL) Annual Congress, CureGene Pharmaceuticals unveiled late-breaking preclinical results for its innovative liver-targeted thyroid hormone receptor beta (THR-β) prodrug, CG-0416. The findings presented in a Late-Breaking Poster session suggest that CG-0416 may redefine treatment approaches not only for obesity but also for metabolic dysfunction-associated steatohepatitis (MASH).

Key Findings from the Preclinical Data


The preclinical results highlighted the triple therapeutic potential of CG-0416, including:
  • - 58% reduction in hepatic lipid accumulation
  • - 66% improvement in weight loss efficacy
  • - 50% lower muscle loss rate compared to standard therapies.

These promising outcomes position CG-0416 as a dual-mechanism candidate, providing a dual approach towards managing both MASH and obesity effectively.

Addressing the Limitations of Current Therapies


Traditional treatments, particularly GLP-1 receptor agonists like semaglutide and tirzepatide, often encounter challenges such as sustaining weight control and preserving muscle mass. CG-0416 seeks to overcome these limitations by targeting specific metabolic pathways with precision, thus enhancing effectiveness.

Innovations of CG-0416


Enhanced Safety Profile


CG-0416 is designed for liver-specific activation, achieving active metabolite concentrations in the liver that are 20 times higher than those found in peripheral tissues. This targeted approach minimizes systemic activation of THR-β, significantly improving long-term safety compared to existing therapies.

Muscle Preservation Breakthrough


In a 26-week diet-induced obesity (DIO) murine model study, CG-0416, when combined with low-dose semaglutide, exhibited a 66% greater fat mass reduction compared to semaglutide alone. Moreover, it maintained a muscle-to-fat loss ratio of 0.18 kg/kg, demonstrating superior muscle preservation compared to existing treatment options which typically range from 0.35 to 0.63 kg/kg.

Advantages for Clinical Application


1. Dual-Pathway Synergy: CG-0416 boosts GLP-1-medicated hepatic lipid oxidation while also activating the IGF-1/Akt/FOXO3a pathway to inhibit muscle breakdown.
2. Possible Oral Administration: With 92% oral bioavailability, CG-0416 could pave the way for the first oral combination treatment with GLP-1 agonists, significantly improving patient compliance and treatment options.

CG-0416 drew considerable attention during its debut at the EASL Congress, thanks to its robust preclinical validation and innovative design. The compound sets a new benchmark in the treatment of metabolic diseases by effectively reprogramming metabolic pathways while prioritizing safety.

Overview of CG-0416


CG-0416 is a novel THR-β prodrug specifically designed for MASH and obesity-related complications. Its unique mechanism of tissue-selective activation addresses issues related to hepatic lipid accumulation, inflammation, and fibrosis. Preclinical studies suggest it performs better than other competitors like resmetirom and VK-2809 in maintaining metabolic control. As it emerges as a potential oral adjunct to GLP-1 therapies, CG-0416 combines rapid fat reduction with muscle preservation, establishing itself as a next-generation metabolic modulator.

About CureGene


Founded in 2018, CureGene is a biotech company based in China, with a global focus and research offices in both China and the United States. The organization has made significant strides in the fields of cardio-cerebrovascular and antiviral diseases, developing innovative platforms and a pipeline of novel drugs that hold substantial market promise. With a mission-driven approach, CureGene has garnered a team of highly distinguished scientists and efficiently transitioned from a research-stage startup to a clinical-stage biotech company, with all its drug pipelines showcasing the potential for First-in-Class or Best-in-Class development.

For further information on CG-0416 and upcoming developments, please visit CureGene's official website.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.